Company profile: Pierian Biosciences
1.1 - Company Overview
Company description
- Provider of cancer diagnostics, including ChemoINTEL, a chemosensitivity assay that measures tumor cell apoptotic response to cytotoxic agents to aid chemotherapy selection; ImmunoINTEL, a flow cytometry-based platform that characterizes and quantifies immune and tumor cell populations for immunotherapy selection; and PathwayINTEL, a proteomic profiling assay that identifies oncogenic drivers to help select targeted or biologic therapies.
Products and services
- PathwayINTEL: A proteomic profiling assay that identifies oncogenic drivers and helps select targeted or biologic therapies for cancer patients
- ImmunoINTEL™: A flow cytometry-based platform that characterizes and quantifies immune and tumor cell populations, delivering insights for immunotherapy selection
- ChemoINTEL™: A chemosensitivity assay that measures the apoptotic response of tumor cells to various cytotoxic agents, aiding in the selection of effective chemotherapy treatments
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pierian Biosciences
Coordination Pharma
HQ: United States
Website
- Description: Provider of nanoparticle-based anticancer therapies, including CPI-100, which delivers immunostimulatory chemotherapeutic combinations directly to tumors. Offers the NCP platform using nanoscale coordination polymers to develop products targeting solid tumors, and seeks partnership opportunities to enhance current cancer immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coordination Pharma company profile →
Tharimmune
HQ: United Kingdom
Website
- Description: Provider of development-stage therapeutics for cancer and chronic pruritus, including TH104, a transmucosal buccal film with nalmefene targeting µ- and kappa-opioid receptors and inhibiting IL-17 for pruritus in PBC and other conditions; TH3215, a bispecific HER2/HER3 antibody; and TH1940, an anti-PD-1 Picobody therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tharimmune company profile →
Aptevo Therapeutics
HQ: United States
Website
- Description: Provider of bispecific immunotherapies and platform technologies for cancer treatment, focused on oncology and hematology. Portfolio includes ADAPTIR and ADAPTIR-FLEX platforms, plus candidates APVO436 (CD3xCD123, Phase 2 AML), APVO603 (4-1BB/OX40), APVO442 (PSMA/CD3 for prostate cancer), and APVO711 (PD-L1/CD40).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aptevo Therapeutics company profile →
CatalYm
HQ: Germany
Website
- Description: Provider of immunotherapies for cancer, developing Visugromab (CTL-002), a monoclonal antibody targeting GDF-15 to counteract immunosuppression in the tumor microenvironment and enhance immune cell infiltration against solid tumors, and running GDFATHER-2 Phase 2 trials evaluating Visugromab with nivolumab in patients relapsed or refractory to anti-PD-1/PD-L1 therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CatalYm company profile →
AltruBio
HQ: United States
Website
- Description: Provider of targeted antibody therapeutics for cancer and immune related inflammatory diseases, including ALTB-168, a humanized antibody targeting late-stage, chronically activated T cells with clinical efficacy in psoriasis, psoriatic arthritis, ulcerative colitis, and acute graft versus host disease, and ALTB-268, a second-generation antibody in trials for ulcerative colitis and psoriatic arthritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AltruBio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pierian Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pierian Biosciences
2.2 - Growth funds investing in similar companies to Pierian Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pierian Biosciences
4.2 - Public trading comparable groups for Pierian Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →